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Abstract 11 Understanding the regulation of development can help elucidate the pathogenesis behind many 12 developmental defects found in humans and other vertebrates. Evidence has shown that 13 alternative splicing of messenger RNA (mRNA) plays a role in developmental regulation, but our 14 knowledge of the underlying mechanisms that regulate alternative splicing are inadequate. 15 Notably, a subset of small noncoding RNAs known as scaRNAs (small cajal body associated RNAs) 16 contribute to spliceosome maturation and function through covalently modifying spliceosomal 17 RNAs by either methylating or pseudouridylating specific nucleotides, but the developmental 18 significance of these modifications is not well understood. Our focus is on one such scaRNA, 19 known as SNORD94 or U94, that methylates one specific cytosine (C 62 ) on spliceosomal RNA U6, 20 thus potentially altering spliceosome function during embryogenesis. We previously showed that 21 mRNA splicing is significantly different in myocardium from infants with congenital heart defects 22 (CHD) compared to controls. Furthermore, we showed that modifying expression of scaRNAs 23 alters mRNA splicing in human cells, and zebrafish embryos. Here we present evidence that 24 SNORD94 levels directly influence levels of methylation at C 62 in U6, which we have previously 25 shown is associated with altered splicing and congenital heart defects. The potential importance 26 of scaRNAs as a developmentally important regulatory mechanism controlling alternative splicing 27 of mRNA is unappreciated and needs more research. 28 Author summary 29 Splicing of mRNA transcripts by removal of introns and some non-critical exons is a crucial part 30 of mRNA processing, gene expression, and cell function, and regulation of this process is still Introduction 43 Congenital heart defects are structural problems in the heart that are present at birth that affect 44 normal function and blood flow through the heart [1] . Nearly 1% of children are born with a 45 congenital heart defect (CHD) every year, making it the most common type of birth defect [1] . 46 Despite how common these defects are, a resounding majority (>70%) of CHDs have unknown 47 etiology to date [2] . The most common complex CHD is tetralogy of Fallot (TOF), which is a 48 combination of four defects and has an incidence of 5 to 7 in every 10,000 live births (5% to 7% 49 of all congenital heart lesions) [1, 3] . TOF includes pulmonary stenosis, a large ventricular septal 50 defect, an overriding aorta, and right ventricular hypertrophy. The result of this condition is 51 oxygen-poor blood from the right ventricle being pumped into the aorta rather than the 4 52 pulmonary artery, and an overworking of the right ventricle that causes the hypertrophy [1] . TOF 53 is treated with surgical intervention, the first of which occurs within the first year of life with 54 potential further or repeated surgeries later in life. 55 Chromosomal defects and single gene disorders are known to cause some CHDs, often in the 56 context of multisystem diseases [2] . Genetic mechanisms underlying nonchromosomal or non-57 Mendelian "sporadic" CHD are poorly understood although these sporadic cases account for the 58 majority of CHDs [3] . Occurrence of CHD in children of mothers with TOF is approximately 3.1%, 59 which is significantly higher than the overall occurrence, supporting a genetic contribution; 60 however, the exact basis is not yet understood [3] . Children with sporadic CHD are most often 61 born to unaffected parents, suggesting incomplete penetrance which can be a consequence of 62 differences in genetic buffering capacity between individuals [3-5]. Also, de novo events, 63 including sequence alteration or copy number changes, can have an impact on gene function or 64 alter dosage and contribute to mutational load [3] . Additionally, recessive mutations, when 65 homozygous, can further destabilize regulatory networks [3] . This makes identification of human 66 disease genes involved in sporadic CHD by classical positional genetics very difficult, and so other 67 approaches are needed. 68 During embryonic development, spatiotemporal signaling between the first and second heart 69 field gives rise to the left and right ventricles and conotruncal outflow tract, which is critical for 70 correct development of the vertebrate heart [6] . The genetic factors implicated in sporadic CHD 71 have been reviewed previously, but these known genetic factors still account for a small 72 percentage of TOF cases [7] . We examined alternative splicing of the transcriptome in heart 73 tissue from infants with TOF. We focused on important regulatory genes involved in heart 74 development in particular (GATA4, MBNL1, MBNL2, DICER, DAAM1, and NOTCH2), and showed 75 that the alternative splice isoforms of these genes were abnormal in TOF patients compared to 76 control, and they were in fact more similar to fetal tissue splice isoforms [8] . We hypothesized 77 that regulatory pathways may be disrupted by alternative splicing, contributing to developmental 78 disorganization. 79 Many human diseases are the result of aberrant pre-mRNA splicing and therefore understanding 80 splicing on a molecular level is of medical relevance [9] . Several studies have shown that mRNA 81 splicing is highly dynamic and intricately regulated during vertebrate heart development [10] [11] [12] [13] . 82 Particularly, the transition from fetal to postnatal patterns of a conserved set of alternatively 83 spliced isoforms has been shown to be critical for proper mouse heart development [14] . It is 84 apparent that alternative mRNA splicing plays a crucial role in heart development, but the role in 85 human heart pathology is not yet clear. Recently, evidence has begun to mount that spliceosome 86 maturation processes contributing to splicing fidelity may play a critical role in mRNA isoform 87 transitions during vertebrate heart development [6] . 88 The spliceosome is a multimegalodalton ribonucleoprotein complex comprised of several 89 subunits (U1, U2, U4, U5, and U6) that carries out specific mRNA processing including splicing of For the purpose of this study, we will focus on SNORD94, which is a C/D box scaRNA and targets 107 a cytosine at position 62 (C 62 )on spliceosomal RNA (snRNA) U6 for 2'-O-methylation [19] . The 2'-108 O-methylation at C 62 on snRNA U6 lies within the stem-loop structure of the catalytic site of the 109 activated U6 RNP, potentially contributing to the catalytic site structure and function and 110 influencing the spliceosome's ability to splice correctly. 111 Previously, it has been shown that snoRNA expression is different in the right ventricular tissue 112 of children with TOF, with 135 snoRNAs being significantly differently expressed from control 113 tissue, most of which having decreased expression in TOF samples [3] . In fact, a similarity in 114 expression levels of most snoRNAs between children with TOF and fetal tissue has been shown, 7 115 with 115 out of 126 snoRNAs with decreased expression and 6 out of 9 with increased expression 116 relative to control tissue [3] . Of those snoRNAs with decreased expression in patients with TOF, 117 6 targeted 5 nucleotides (of 8 total) on U6 according to the snoRNA database [3, 18] . SNORD94 118 was among these snoRNAs with reduced expression in children with TOF as well as fetal tissue 119 relative to right ventricular tissue from normally developing infants. We hypothesize that 120 SNORD94 expression level along with the other scaRNAs is important for spliceosomal function 121 and may therefore may play a role in regulating heart development.
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Of note, there are other known sites of 2'-O-ribose methylation within spliceosomal RNA U6 123 ( Figure 1 ). The scaRNAs that modify C 60 , HBII-166 (SNORD67), has been shown to have reduced 124 expression in RV tissue from infants with TOF, but the scaRNA that modifies C 77 , mgU6-77 125 (SNORD10), is not known to have altered expression in RV tissue from infants with TOF [3, 8] . In the same snoRNA expression study, it was also shown that U6 had reduced expression by 3.2-132 fold in all 16 TOF samples as compared to control [3] . Analysis of splicing variation showed a 133 substantial disturbance in splicing of genes known to be critical for heart formation, and many of 134 these were in common with fetal patterns [3, 8] . This dramatic shift in ncRNA expression and in low dNTP concentration is reduced in quantity when methylation is high. 163 We validated the technique for quantifying methylated cytosine by using synthesized sequences 164 corresponding to the sequence from human U6. RNA oligos were custom synthesized by IDT 165 (Integrated DNA Technologies; Coralville, Iowa) and corresponded to the sequence of whole 166 human U6. One oligonucleotide was methylated at C 62 (mC 62 ) and the other was unmethylated. 167 We used 0.1ng RNA for each RT reaction (instead of 50ng as with the total RNA samples). We 168 compared the cycle change for long fragments in low vs normal dNTP concentrations (ΔC t long 169 fragments) and found that the difference is significantly greater when methylation is higher. We 170 also found that there exists a nonzero ΔC t when no methylation is present, showing there is some 171 loss in overall RT efficiency in low dNTP concentration. 172 Figure 3 shows the observed ΔC t value for the difference in long fragment quantity between 173 normal and low dNTP concentrations with synthesized fragment with either 100% methylation 174 at C 62 on U6 or 0% methylation. 175 We analyzed the data from all groups using t tests for the difference between groups. Because In our in vitro assessment of altered levels of SNORD94, we found that knockdown of SNORD94 200 in primary cardiomyocytes derived from a normally developing heart caused a significant 201 decrease in methylation at C 62 (P<0.05) ( Figure 5 ). Finally, we found that over expression of 202 SNORD94 in primary cardiomyocytes from a patient with TOF showed an increased level of 203 methylation at C 62 on U6, however this difference was not significant at this sample size (P=0.12) 204 ( Figure 5) 
Discussion
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Alternative splicing has a significant impact on developmental pathways in multiple organ 229 systems, including the heart. We have shown that methylation at C 62 on U6 is reduced in right 230 ventricle tissue of children with TOF as compared to control. We have also confirmed that 231 changing levels of SNORD94 in cell culture produces a corresponding change in methylation at 232 C 62 within spliceosomal RNA U6. These findings taken together suggest a dysfunction in an 233 important regulatory pathway that is responsive to scaRNA expression levels. Directly stated, 234 our accumulated results suggest that dysregulated scaRNA levels contribute to defective heart 235 development by disturbing proper alternative splicing of mRNAs. This study focused on one 236 specific scaRNA producing one biochemical modification, but more research is necessary to 237 determine the interplay of multiple scaRNAs on spliceosomal integrity. 238 Our previous studies provided evidence that modest dysregulation of scaRNA expression 239 impacted mRNA alternative splicing and development [3, 6, 8, 23 ]. Here we present evidence 240 that there is a direct connection between the expression level of a single scaRNA and the level of 241 methylation at its target nucleotide. This provides supporting evidence that the level of scaRNA 242 expression directly influences alternative splicing through its biochemical function. Collectively 243 these data suggest that there is likely a biological threshold of accumulated change in scaRNA 244 expression that may be important contributors to heart defects. and no stop occurs. This kit contains a stem-loop reverse transcription primer and a mix of 300 forward and reverse PCR primers with TaqMan probes for use with PCR (shown in Figure 6 ). The 301 custom TaqMan Small RNA Assay Kit was used according to manufacturer's protocol except for 302 two notable exceptions: reducing dNTP concentration to 1µM in the "low dNTP concentration" 303 group as compared to 1mM concentration in the "normal dNTP concentration" group and using 304 50ng total RNA per reaction rather than the recommended 10ng because the reduced dNTP 305 concentration also tends to cause a reduction in overall reverse transcription. In total, for each 306 RNA sample there were 2 different reactions created using either the RT kit, and either normal 307 or low concentration of dNTP. RNA was split from the same aliquot for each RT reaction.
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Quantitative Real-Time PCR was then performed using the ViiA 7 from Applied Biosystems using 309 standard conditions and an annealing temperature of 60°C. 
